4.6 Article

Identification and evaluation of novel serum autoantibody biomarkers for early diagnosis of gastric cancer and precancerous lesion

Journal

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume 149, Issue 11, Pages 8369-8378

Publisher

SPRINGER
DOI: 10.1007/s00432-023-04732-z

Keywords

Gastric cancer; Precancerous lesion; Autoantibody; Serum biomarker; Early diagnosis

Categories

Ask authors/readers for more resources

In this study, novel serum autoantibody-based biomarkers for precancerous lesion and early gastric cancer were identified. The identified autoantibodies showed higher levels in patients compared with healthy individuals and had good potential for differentiating between different stages of gastric cancer. Predictive models incorporating these autoantibodies improved the diagnostic efficiency for early detection of gastric cancer and precancerous lesion.
PurposeEarly diagnosis is crucial for optimal prognosis of gastric cancer (GC). Hereby, we aimed to identify novel serum autoantibody-based biomarkers for precancerous lesion (PL) and early GC.MethodsWe performed serological proteome analysis (SERPA) combined with nanoliter-liquid chromatography combined with quadrupole time of flight tandem mass spectrometry (Nano-LC-Q-TOF-MS/MS) to screen for GC-associated autoantibodies. The identified autoantibodies were analyzed for potential detection value for PL and GC by enzyme-linked immunosorbent assay (ELISA). Receiver operating characteristic (ROC) curves analysis was conducted to evaluate the accuracy of the biomarkers.ResultsWe identified seven candidates, such as mRNA export factor (RAE1), Nucleophosmin 1 (NPM1), phosphoglycerate kinase 1 (PGK1), and ADP-ribosylation factor 4 (ARF4). Antibodies against all seven proteins were present at higher levels in sera from 242 patients (51 PL, 78 early GC, 113 advanced GC) compared with sera from 122 healthy individuals. RAE1-specific autoantibody discriminated best between patients at different GC stages, with area under the curve (AUC) values of 0.710, 0.745, and 0.804 for PL, early GC, and advanced GC, respectively. Two predictive models composed of gender, RAE1, PGK1, NPM1, and ARF4 autoantibodies (Model 2 for PL) and of age, gender, RAE1, PGK1, and NPM1 autoantibodies (Model 3 for early GC) had improved diagnostic efficiencies, with AUCs of 0.803 and 0.857, sensitivities of 66.7% and 75.6%, and specificities of 78.7% and 87.7%, respectively.ConclusionThe identified serum tumor-associated autoantibodies (TAAbs) may have good potential for early detection of GC and PL.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available